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Bartonella quintana is a gram-negative microorganism that causes trench fever and chronic bacteremia. B.
quintana lipopolysaccharide (LPS) was unable to induce the production of proinflammatory cytokines in
human monocytes. Interestingly, B. quintana LPS is a potent antagonist of Toll-like receptor 4 (TLR4), as it
inhibited both mRNA transcription and the release of tumor necrosis factor alpha, interleukin 1 (IL-1), and
IL-6 by Escherichia coli LPS in human monocytes, at ratios ranging from 1,000:1 to 10:1 (B. quintana LPS to
E. coli LPS). Likewise, B. quintana LPS blocked the interaction of E. coli LPS with TLR4 in transfected cell
lines. The extent of the inhibitory effect of B. quintana LPS was demonstrated in microarray studies, which
showed downregulation of practically all genes induced by LPS in monocytes. Because of the role of TLR4 in
inflammation, B. quintana LPS may prove useful as a potent anti-TLR4 agent with therapeutic potential in both
infections and autoimmune inflammation.
Bartonella quintana is a gram-negative pathogen initially de-
scribed during World War I as the agent of trench fever, a
disease associated with recurrent fever and headaches. In the
past few decades, B. quintana infection has been identified in
homeless people (4). While most individuals with B. quintana
infection recover, some 5 to 10% eventually develop chronic
bacteremia (4) and subsequent complications, such as chronic
endocarditis in the absence of preexisting heart valve lesions
(20). New manifestations of B. quintana infections, such as
bacillary angiomatosis, bacillary peliosis hepatitis, and chronic
lymphadenopathy, have also been described (2). These mani-
festations have been attributed to proliferative and antiapop-
totic effects of Bartonella spp. (6).
A characteristic of B. quintana bacteremia is the absence of
symptoms of high fever and signs of septic shock, disseminated
intravascular coagulation, or organ failure. Lipopolysaccharide
(LPS, or endotoxin) is a main component of the outer mem-
branes of gram-negative microorganisms, and the LPSs from
gram-negative enteric bacteria (such as Escherichia coli and
Salmonella enterica) are able to induce proinflammatory cyto-
kines, chemokines, and adhesion molecules (23) and thereby to
evoke the clinical signs of sepsis. The lipid A moiety of LPS
interacts with a membrane receptor complex containing Toll-
like receptor 4 (TLR4), MD-2, and CD14 (17, 19, 23). Because
of strong proinflammatory effects of most species of LPS, the
apparent absence of sepsis syndrome in patients with B. quin-
tana bacteremia is a puzzling aspect of the infection. As an
explanation, overproduction of the anti-inflammatory cytokine
interleukin-10 (IL-10) and an attenuated inflammatory cyto-
kine profile during B. quintana bacteremia have been proposed
(5), but the molecular mechanisms have remained elusive.
Recently, the LPS of the related organism Bartonella
henselae was purified and characterized as a penta-acylated
deep-rough LPS with low endotoxic activity (17, 27). In the
present study, we investigated the biologic activities of B. quin-
tana LPS in terms of induction of proinflammatory cytokines
and interaction with TLRs and other species of LPS.
MATERIALS AND METHODS
Reagents and microorganisms. LPS (E. coli serotype O55:B5) was purchased
from Sigma Chemical Co., and synthetic Pam3Cys was purchased from EMC
Microcollections (Tu¨bingen, Germany). The B. quintana Oklahoma strain was
kindly provided by D. Raoult (Marseille, France) and grown on sheep blood agar
at 37°C in a 5% CO2 atmosphere. For stimulation experiments, 5-day cultures of
B. quintana were heat killed for 60 min at 56°C. B. quintana LPS was extracted
either by a single-step phenol-water extraction, as previously described (13), or
by a two-step extraction method (9) which eliminates contamination with pro-
teins. E. coli LPS from Sigma was also double purified (9). Both purified and
nonpurified E. coli and B. quintana LPSs (100 g of each) were run in a 10%
polyacrylamide gel and subjected to silver staining to visualize contaminating
proteins. Briefly, the gel was fixed in 40% methanol–10% acetic acid, sensitized
using 0.2% sodium thiosulfate, and then stained with 0.2% silver nitrate for 20
min. Color was developed using a 3% sodium carbonate solution.
Signaling through human TLR2 and TLR4 in a transfected cell line. Chinese
hamster ovary (CHO) fibroblasts stably transfected with human CD14 (3E10-
CD14), a combination of CD14 and TLR4 (3E10-TLR4), and TLR2 (3E10-
TLR2) were a kind gift from Robin Ingalls. These cell lines express inducible
membrane CD25 under the control of a region of the human E-selectin
(ELAM-1) promoter containing NF-B binding sites. Cells were maintained at
37°C in 5% CO2 in Ham’s F-12 medium (Gibco, Invitrogen, Breda, The Neth-
erlands) supplemented with 10% fetal calf serum, 0.01% L-glutamine, 50 g/ml
gentamicin, 400 U/ml hygromycin, and 0.5 mg/ml of G418 (for 3E10-TLR2) or
0.05 mg/ml of puromycin (for 3E10-TLR4) as an additional selection antibiotic.
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TLR4 expression was confirmed by flow cytometry (Coulter Epics XL-MCL;
Beckman Coulter, Mijdrecht, The Netherlands), using a phycoerythrin-labeled
anti-TLR4 antibody (clone HTA125; Immunosource, Halle-Zoersel, Belgium).
For stimulation experiments, 500 l of cells in culture medium at a density of
1  105/ml was plated in 24-well culture plates. After an overnight incubation,
cells were incubated with control medium, Pam3Cys (10 g/ml), E. coli LPS (1
g/ml), B. quintana LPS (10 g/ml), or a combination of E. coli LPS and B.
quintana LPS for 20 h at 37°C. Thereafter, cells were harvested using trypsin-
EDTA (Cambrex, East Rutherford, NY) and prepared for flow cytometry
(Coulter FACScan). CD25 expression of the CHO cells was measured using
fluorescein isothiocyanate-labeled anti-CD25 (DAKO, Glostrup, Denmark) and
was expressed as the x-fold increase above the mean.
Isolation of PBMC and stimulation of cytokine production. After informed
consent was obtained, venous blood was drawn from the cubital veins of six
healthy volunteers into three 10-ml lithium-heparin tubes (Monoject, ’s Herto-
genbosch, The Netherlands). The regional medical ethical committee approved
the study protocol. The peripheral blood mononuclear cell (PBMC) fraction was
obtained by density centrifugation of blood diluted 1:1 in pyrogen-free saline
over Ficoll-Paque (Pharmacia Biotech AB, Uppsala, Sweden). Cells were washed
twice in saline and suspended in culture medium (RPMI 1640 DM) supple-
mented with 10 g/ml gentamicin, 10 mM L-glutamine, and 10 mM pyruvate. The
cells were counted in a Coulter counter (Beckman Coulter, Mijdrecht, The
Netherlands), and the number was adjusted to 5  106 cells/ml.
PBMC (5  105) in a 100-l volume were added to round-bottomed 96-well
plates (Greiner, Alphen a/d Rijn, The Netherlands) and incubated with either
100 l of culture medium (negative control) or one of the following stimuli: B.
quintana bacteria (1  106 microorganisms/ml), B. quintana LPS (at concentra-
tions of up to 10 g/ml), and E. coli LPS (10 ng/ml). To assess the role of TLR4
in the induction of cytokines by B. quintana LPS, PBMC were preincubated for
30 min with 10 g/ml control immunoglobulin G1 (IgG1) or a blocking anti-
TLR4 antibody (eBioscience, AMDS Malden, The Netherlands). Similarly, the
TLR4 antagonistic properties of B. quintana LPS were assessed by preincubating
the cells with various concentrations of B. quintana LPS 30 min before stimula-
tion with E. coli LPS.
Cytokine measurements. Human tumor necrosis factor alpha (TNF-), IL-1,
L-8, and IL-6 concentrations were measured by use of commercial enzyme-
linked immunosorbent assay kits (Pelikine Compact, CLB, Amsterdam, The
Netherlands) according to the manufacturer’s instructions.
RNA extraction. Total RNA was extracted from 10  106 cells by using 1 ml
TRIzol reagent (Sigma, St. Louis, MO). Subsequently, 200 l chloroform and
500 l 2-propanol (Merck, Darmstadt, Germany) were used to separate the
RNAs from DNAs and proteins. Finally, after a wash step with 75% ethanol
(Merck, Darmstadt, Germany), the dry RNAs were dissolved in 30 l of water.
PCR amplification. To obtain cDNA, we reverse transcribed 1 g DNase-
treated total RNA with oligo(dT) primers (0.01 g/ml) in a reverse transcription-
PCR mixture with a total volume of 20 l. Subsequently, quantitative PCR was
performed using an ABI PRISM 7000 sequence detection system (Applied
Biosystems, Foster City, CA). PCRs to amplify glyceraldehyde-3-phosphate de-
hydrogenase, IL-1, TNF-, and IL-6 were performed with SYBR green PCR
master mix (Applied Biosystems, Foster City, CA), 5 l diluted (1/20) cDNA,
and primers at a final concentration of 300 nmol/liter in a total volume of 25 l.
The following primers were developed using Primer Express (Applied Biosys-
tems, Foster City, CA): CCTCTGATGGCACCACCAG (reverse primer) and
TCTTCTCGAACCCCGAGTGA (forward primer) for TNF-, GGCAAGTCT
CCTCATTGAATCC (reverse primer) and AGCCCTGAGAAAGGAGACA
TGTA (forward primer) for IL-6, and TGGGTAATTTTTGGGATCTACA
CTCT (reverse primer) and AATCTGTACCTGTCCTGCGTGTT (forward
primer) for IL-1. Quantification of the PCR signals for each sample was per-
formed by comparing the cycle threshold values, in duplicate, for the gene of
interest with the cycle threshold values for the glyceraldehyde-3-phosphate de-
hydrogenase housekeeping gene. We validated all primers according to the
protocol, and the standard curves were all within the dynamic range.
Microarray analysis. PBMC from two different healthy donors were preincu-
bated or not with 500 ng/ml B. quintana LPS for 1 h and, thereafter, were left
untreated for 8 h or treated with 1 ng/ml E. coli LPS. RNAs were extracted by the
TRIzol method (Sigma, St. Louis, MO). Protocols from Affymetrix (Santa Clara,
CA) (1a) were followed as described previously, with some modification, as
briefly described below (21). Synthesis and labeling of double-stranded cDNA
from 1 g total RNA were performed through one-cycle amplification in vitro
transcription/biotin labeling using a MessageAmp II aRNA amplification kit
(Ambion, Austin, TX). After fragmentation, the hybridization mixture was
spiked with Bio B, C, and D and cre and hybridized to human genome array
U133 Plus2.0 (Affymetrix, Santa Clara, CA), containing over 47,000 probes.
After 16 h, hybridization arrays were washed and incubated with streptavidin-
coupled phycoerythrin (Molecular Probes, Eugene, OR). The GeneChips were
then scanned using a GeneChipScanner laser scanner (Affymetrix, Santa Clara,
CA) according to the manufacturer’s instructions and were analyzed by using
GCOS (Affymetrix, Santa Clara, CA). Normalization, model fitting, and filtering
were performed by using dChip (Harvard) (12). Subsequently, pairwise and
multiple comparisons were performed by dChip, applying different criteria
(1.2-fold change with P value of 	0.05 and/or 2-fold change with P value of
	0.05). High-level analyses such as cluster analysis, principal component anal-
ysis, and analysis of variance were performed by dChip on filtered genes and a
gene list generated by multiple comparisons. Hierarchical cluster analysis was
performed using algorithms that assemble all elements in a single tree based on
computed similarity scores.
Statistical analysis. The differences between groups were analyzed by the
unpaired Student t test and, where appropriate, the paired t test. The level of
significance between groups was set to P values of 	0.05. The data are given as
means 
 standard deviations (SD).
RESULTS
Role of TLR2 and TLR4 in recognition of B. quintana. The
first sets of experiments were designed to explore the induction
of proinflammatory cytokines by whole B. quintana microor-
ganisms and the role of TLR2 and TLR4 in this induction.
Interestingly, heat-killed B. quintana did not stimulate TLR4-
transfected CHO cells, while TLR2-transfected CHO cells re-
acted to B. quintana, indicating that the microorganism is able
to signal through this receptor (Fig. 1A to D). To further assess
the biological significance of these findings, we investigated the
production of proinflammatory cytokines by human PBMC
upon stimulation with heat-killed B. quintana. As shown in Fig.
1E, a blocking TLR4 antibody did not influence the capacity of
B. quintana to stimulate the production of TNF-, IL-1, and
IL-6 from human PBMC. This finding implies that the stimu-
lation of cytokines by B. quintana is not induced by its LPS
component or that B. quintana LPS stimulates cytokines
through a TLR4-independent mechanism.
B. quintana LPS is a TLR4 antagonist. To investigate the
two above-mentioned possibilities, we isolated B. quintana LPS
in a two-step purification process which warrants the absence
of protein contaminants (14). The purity of both E. coli and B.
quintana LPSs after the two-step purification was determined
using silver staining for proteins. Silver staining revealed the
absence of any protein contaminants in both LPS samples after
purification (Fig. 2A). As shown in Fig. 2B, purified B. quin-
tana LPS did not stimulate the production of TNF-, IL-1,
and IL-6 in human PBMC. IL-8 was also not induced by B.
quintana LPS (not shown). Similar negative results were ob-
tained when peritoneal murine macrophages were stimulated
(not shown). These results demonstrate that B. quintana LPS is
not able to induce cytokine production and suggest that it is
devoid of direct biological activity.
It was shown previously that certain LPS structures with no
direct agonistic activity can function as TLR4 antagonists. To
assess whether B. quintana LPS also functions as a TLR4
antagonist, we preincubated human PBMC with various con-
centrations of B. quintana LPS before stimulating the cells with
E. coli LPS. As shown in Fig. 3A, B. quintana LPS completely
abolished E. coli LPS-induced TNF- production when ratios
of at least 10:1 were used and inhibited the induction of cyto-
kines approximately 50% when a 1:1 ratio of B. quintana LPS
to E. coli LPS was employed. In addition, when a 10:1 ratio was
used, B. quintana LPS was able to completely inhibit the ex-
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pression of proinflammatory cytokine TNF-, IL-1, and IL-6
mRNAs from E. coli LPS-challenged human PBMC (Fig. 3B).
The inhibitory effect of B. quintana LPS was exerted by block-
ing TLR4, as further demonstrated by the blockade of E. coli
LPS-induced stimulation of CHO cells transfected with TLR4
(Fig. 3C). In addition, the effects of B. quintana LPS are tar-
geted specifically to TLR4, since the stimulation of TLR2 was
not influenced by the presence or absence of B. quintana LPS
in the cultures (not shown).
Microarray analysis. We performed oligonucleotide ge-
nome array (Affymetrix) analysis to evaluate the impact of B.
quintana LPS on gene expression on its own and in combina-
tion with E. coli LPS. Cluster analysis revealed that samples
treated with E. coli LPS clustered together, whereas samples
treated with B. quintana LPS or E. coli LPS plus B. quintana
LPS clustered together with the control (Fig. 4A). In spite of
the strong influence of donor differences, the effect of B. quin-
tana LPS was unambiguous, as the expression profile for B.
quintana LPS alone or in combination with E. coli LPS was
hardly different from that of the corresponding control. This
indicated that B. quintana LPS exerted no effect on its own but
totally inhibited the effect of E. coli LPS. The complete mode
of inhibition indeed suggests that B. quintana LPS binds to
TLR4 but does not transduce the signal, hereby acting as a
competitive inhibitor of E. coli LPS. When the effects of dif-
ferent treatments on gene expression were compared, E. coli
FIG. 1. TLR4 is not involved in the host response to B. quintana. CHO cells transfected with CD14, CD14 and TLR4, or CD14 and TLR2 were
stimulated with 1 106 heat-killed B. quintana cells. Expression of CD25 on the cell membrane was measured by fluorescence-activated cell sorting
analysis. B. quintana stimulated CD25 expression only in CHO-CD14/TLR2 cells (B and D), not in CHO-CD14 (A and D) or CHO-CD14/TLR4
(C and D) cells. (E) Human PBMC were stimulated for 24 h with 1  106 heat-killed B. quintana microorganisms/ml in the presence of either
control IgG1 (open bars) or an anti-TLR4 antibody (aTLR4) (10 g/ml; hatched bars). Unstimulated cells are presented as solid bars.
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LPS regulated 679 genes (2-fold change and P 	 0.05; both
up- and downregulation) compared to the control (Fig. 4B). In
contrast, B. quintana LPS alone or in combination with E. coli
LPS regulated no single gene compared to the control by these
criteria.
DISCUSSION
In the present study, we show for the first time that the
gram-negative bacterium B. quintana does not trigger host
defense mechanisms via TLR4-dependent pathways and, in-
stead, that its LPS component is a powerful TLR4 antagonist.
Septic shock is often preceded by gram-negative bacteremia,
and the LPS component of these pathogens is known toplay a
crucial role in this respect. Interestingly, B. quintana was pre-
viously described to induce chronic infections (4), whereas
FIG. 3. (A) Human PBMC were stimulated or not for 24 h with E.
coli LPS at a concentration of 10 ng/ml. Before stimulation with E. coli
LPS, the cells were preincubated with either RPMI or B. quintana LPS
at concentrations ranging from 1 to 100 ng/ml. (B) In parallel, PBMC
preincubated with B. quintana LPS at 100 ng/ml and thereafter stim-
ulated with E. coli LPS at 10 ng/ml were used for mRNA measure-
ments of proinflammatory cytokines. (C) The findings were also con-
firmed in CHO cells transfected with either human CD14 or a
combination of human TLR4 and human CD14, which were stimu-
lated with E. coli LPS (1 g/ml), B. quintana LPS (10 g/ml), or a
combination of both. Expression of CD25 on the cell membrane was
measured by fluorescence-activated cell sorting analysis. The TLR2
agonist Pam3Cys (5 g/ml) served as a negative control stimulus. Data
are presented as means 
 SD (n  6).
FIG. 2. (A) Silver staining of E. coli and B. quintana LPSs before
and after double purification (100 g of each LPS). Two micrograms
of bovine serum albumin (BSA) was also loaded into the gel as a
control for staining. (B) Human PBMC were stimulated for 24 h with
E. coli LPS (10 ng/ml; open bars) or B. quintana LPS (1 g/ml; hatched
bars). Unstimulated cells are presented as solid bars. Data are pre-
sented as means plus SD (n  6).
4834 POPA ET AL. INFECT. IMMUN.
FIG. 4. (A) PBMC were isolated from two individual donors (1 and 2). They were preincubated or not with B. quintana LPS (Inh) for 15 min
and thereafter stimulated or not with E. coli LPS (LPS). The numbers designate the donor origins. Gene expression profiling was performed and
analyzed as described in Materials and Methods. Hierarchical cluster analysis was performed on genes (vertical dendrogram) and samples
(horizontal dendrogram) according to the algorithm described in Materials and Methods to visualize the gene expression patterns and relatedness
of samples. Red, upregulation; blue, downregulation; white, average regulation. The magnified view in the box shows sample information in color
blocks (first row, individual sample color code; second row, treatment groups, with dark green for control, light green for LPS, dark brown for
inhibitor alone, and light brown for LPS plus inhibitor; third row, treatment groups, with dark and light gray for with and without E. coli LPS,
respectively) and clustering of samples according to the gene expression profiles. (B) Samples were compared to the control, and the numbers of
differentially expressed genes were determined using the criteria of a 2-fold change and a P value of 	0.05. The number above each bar indicates
the number of differentially expressed genes.
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signs of an important acute response were absent in those
infected with the pathogen (2, 20). In line with this, the results
of our present study strongly suggest that TLR4 is not involved
in the host defense against B. quintana, and this fact might also
be responsible for the absence of hypotension and shock in B.
quintana-infected persons. The limited role of LPS-TLR4 in-
teraction in the induction of an immune response to Bartonella
spp. is not singular to B. quintana, since previous reports indi-
cated that other systems, such as the proteinaceous VirB type
IV secretion system (17), outer membrane proteins (8), and
BadA (22), are more responsible than LPS for the stimulation
of cytokines by the related microorganism B. henselae. In line
with this, recent evidence suggests that evading TLR4-depen-
dent responses may in fact contribute to the virulence of var-
ious gram-negative bacteria (16). On the other hand, other
LPS species, such as those isolated from Legionella pneumo-
phila, Leptospira interrogans, Helicobacter pylori, and Porphy-
romonas gingivalis (11, 17, 18, 26), interact with TLR2 rather
than with TLR4. In a recent study, we found that cytokine
stimulation by B. quintana is mediated almost entirely by TLR2
(G. Matera et al., submitted for publication), further substan-
tiating the TLR4 independence of B. quintana-induced cyto-
kine production.
Previous studies reported that certain LPS structures could
act as TLR4 antagonists. We investigated whether this could
also be the case for B. quintana LPS. Our results indicated that
interaction of B. quintana LPS with TLR4 does not induce
gene transcription, as demonstrated by the lack of gene regu-
lation in an Affymetrix assay of cells incubated with culture
medium containing B. quintana LPS. This contrasts with the
potent stimulation of a variety of gene families, including the
NF-B proinflammatory cytokine genes, when human umbili-
cal vein endothelial cells (7), but not HeLa229 cells (10), were
stimulated with intact B. henselae microorganisms. This effect
also differs from a recent report in which B. quintana LPS was
indicated to induce the release of the chemokine IL-8 (15),
while also being able to modulate the apoptosis of endothelial
cells (13). One crucial difference with these initial reports is in
the method of LPS purification. Indeed, when we stimulated
PBMC with LPS only partially purified by the single-step
method employed in the previous studies, we also observed
TLR2-dependent stimulation of cytokines (not shown). How-
ever, single-step purification is prone to retain a high percent-
age of protein contaminants in the LPS preparation, which
likely explains this discrepancy. B. quintana LPS is not the only
LPS which is unable to stimulate cytokine production. Re-
cently, another LPS-like molecule derived from Oscillatoria
planktonthrix FP1, termed Cyp, was reported to have antago-
nistic effects on TLR4 (14). Similar properties have been de-
scribed for the LPSs isolated from other microorganisms, such
as Rhodobacter sphaeroides or Chromobacterium violaceum,
which are similar to the lipid A precursor Ia (compound 406)
(25).
The results of our study are the first to report the TLR4
antagonistic effects of an LPS from Bartonella spp. In line with
a low endotoxic potency of an LPS from Bartonella spp., Zahr-
inger and colleagues recently reported that LPS isolated from
B. henselae is a penta-acylated deep-rough LPS with endotoxic
activities at least 1,000-fold less potent than that of S. enterica
LPS (27). B. quintana LPS has a similar deep-rough structure
(24), which may explain part of the absent endotoxic activity.
However, differences with B. henselae LPS must also be
present, as B. quintana LPS is completely unable to stimulate
cytokines at concentrations as high as 10 g/ml. The nature of
these differences remains to be established. It should be noted,
however, that other LPS species with antagonistic properties,
i.e., R. sphaeroides or C. violaceum LPS, have tetra-acylated
lipid A structures (25). As we previously proposed, the three-
dimensional structure of lipid A is responsible for the differ-
ential interaction with TLR4, with strictly cylindrical structures
being antagonists, whereas more conical shapes function as
strong TLR4 agonists (18). In addition, a hexa-acylated biphos-
phoryl LPS is likely to represent the structure that could best
trigger a proinflammatory response upon binding to TLR4
(17). Other LPS structures with antagonistic properties for
human TLR4, such as a mutant LPS from Neisseria meningitidis
(T. Sprong, personal communication), have been shown to be
agonists of murine TLR4. Initial studies suggest that this is not
the case for B. quintana LPS (1).
The role of TLR4 in the pathogenesis of endotoxic shock has
been demonstrated extensively, and recently the receptor was
proposed to be a potential therapeutic target for several auto-
immune diseases, including rheumatoid arthritis (3). In line
with this, the results of our study underline the large potential
of B. quintana LPS for therapeutic use in these diseases.
Firstly, in experiments conducted in vitro, B. quintana LPS
could block E. coli LPS-induced effects at ratios as small as
10:1. Secondly, B. quintana LPS specifically binds TLR4 and
does not interfere with the stimulation of other receptor path-
ways. Finally, unlike studies using a selected number of genes,
the genome array approach enables the evaluation of total
transcript levels in an unbiased way. Therefore, these results
clearly demonstrate that B. quintana LPS is a potent TLR4
antagonist and also suggest that its potential to interfere with
other immunologic pathways, if any, is extremely limited.
Eventually, this might be translated into a limitation in side
effects in the case of therapeutic applications. This may give B.
quintana LPS a significant advantage with respect to other
biological drugs currently on the market.
In conclusion, we demonstrate in the present study that
stimulation of cytokines by B. quintana is independent of both
its LPS component and TLR4. Moreover, while being unable
to stimulate cytokine production, B. quintana LPS is a potent
TLR4 antagonist. Because TLR4 proinflammatory signals are
involved in a variety of pathological inflammatory reactions,
the use of the TLR4 antagonistic properties of B. quintana LPS
may prove of potential therapeutic value.
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